Why all migraine patients should be treated with magnesium.

Alexander Mauskop, Jasmine Varughese
Author Information
  1. Alexander Mauskop: New York Headache Center, 30 East 76 Street, New York, NY 10021, USA. drmauskop@nyheadache.com

Abstract

Magnesium, the second most abundant intracellular cation, is essential in many intracellular processes and appears to play an important role in migraine pathogenesis. Routine blood tests do not reflect true body magnesium stores since <2% is in the measurable, extracellular space, 67% is in the bone and 31% is located intracellularly. Lack of magnesium may promote cortical spreading depression, hyperaggregation of platelets, affect serotonin receptor function, and influence synthesis and release of a variety of neurotransmitters. Migraine sufferers may develop magnesium deficiency due to genetic inability to absorb magnesium, inherited renal magnesium wasting, excretion of excessive amounts of magnesium due to stress, low nutritional intake, and several other reasons. There is strong evidence that magnesium deficiency is much more prevalent in migraine sufferers than in healthy controls. Double-blind, placebo-controlled trials have produced mixed results, most likely because both magnesium deficient and non-deficient patients were included in these trials. This is akin to giving cyanocobalamine in a blinded fashion to a group of people with peripheral neuropathy without regard to their cyanocobalamine levels. Both oral and intravenous magnesium are widely available, extremely safe, very inexpensive and for patients who are magnesium deficient can be highly effective. Considering these features of magnesium, the fact that magnesium deficiency may be present in up to half of migraine patients, and that routine blood tests are not indicative of magnesium status, empiric treatment with at least oral magnesium is warranted in all migraine sufferers.

References

  1. Cephalalgia. 2005 Mar;25(3):199-204 [PMID: 15689195]
  2. Proc Natl Acad Sci U S A. 2001 Apr 10;98(8):4687-92 [PMID: 11287655]
  3. Cephalalgia. 1999 Nov;19(9):802-9 [PMID: 10595290]
  4. Eur J Pharmacol. 1988 Jul 14;151(3):491-5 [PMID: 2463926]
  5. Expert Opin Emerg Drugs. 2006 Sep;11(3):419-27 [PMID: 16939382]
  6. Br J Pharmacol. 1987 Jul;91(3):449-51 [PMID: 3496933]
  7. Clin Chem. 1987 Apr;33(4):518-23 [PMID: 3829383]
  8. Neurosci Lett. 1985 Jan 7;53(1):21-6 [PMID: 2859558]
  9. Clin Physiol. 1994 Sep;14(5):539-46 [PMID: 7820978]
  10. Br J Pharmacol. 1978 Apr;62(4):507-14 [PMID: 418838]
  11. Cephalalgia. 1996 Oct;16(6):436-40 [PMID: 8902254]
  12. Magnes Res. 2001 Dec;14(4):283-90 [PMID: 11794636]
  13. Pain. 1993 Feb;52(2):127-136 [PMID: 8455960]
  14. Stroke. 2002 Dec;33(12):2738-43 [PMID: 12468763]
  15. Headache. 1995 Jan;35(1):14-6 [PMID: 7868328]
  16. Clin Sci (Lond). 1995 Dec;89(6):633-6 [PMID: 8549082]
  17. Headache. 2003 Sep;43(8):901-3 [PMID: 12940813]
  18. Cephalalgia. 1996 Jun;16(4):257-63 [PMID: 8792038]
  19. Headache. 2002 Apr;42(4):242-8 [PMID: 12010379]
  20. Headache. 1995 Nov-Dec;35(10):597-600 [PMID: 8550360]
  21. Headache. 2002 Feb;42(2):114-9 [PMID: 12005285]
  22. Headache. 1996 Mar;36(3):154-60 [PMID: 8984087]
  23. Cephalalgia. 2002 Jun;22(5):345-53 [PMID: 12110110]
  24. Neurosci Lett. 1980 Dec;20(3):323-7 [PMID: 7443079]
  25. Ann Emerg Med. 2001 Dec;38(6):621-7 [PMID: 11719739]
  26. Headache. 2003 Jun;43(6):601-10 [PMID: 12786918]
  27. Headache. 1989 Oct;29(9):590-3 [PMID: 2584000]
  28. Nature. 1987 Oct 1-7;329(6138):395-6 [PMID: 2443852]
  29. Am J Physiol. 1994 Jan;266(1 Pt 2):R158-63 [PMID: 8304537]
  30. Hypertension. 1986 Aug;8(8):694-9 [PMID: 3733214]
  31. Trends Pharmacol Sci. 1994 May;15(5):149-53 [PMID: 7538702]
  32. Headache. 1991 May;31(5):298-301 [PMID: 1860787]
  33. Brain. 2006 Mar;129(Pt 3):778-90 [PMID: 16364954]
  34. Am J Clin Nutr. 1981 Nov;34(11):2364-6 [PMID: 7197877]
  35. Brain Res. 1996 Nov 18;740(1-2):268-74 [PMID: 8973824]
  36. Crit Care Nurs Q. 2000 Aug;23(2):1-19; quiz 87 [PMID: 11853022]
  37. Neurosci Lett. 1999 May 14;266(3):173-6 [PMID: 10465701]
  38. Methods Find Exp Clin Pharmacol. 1992 May;14(4):297-304 [PMID: 1507932]

MeSH Term

Analgesics
Humans
Magnesium
Magnesium Deficiency
Migraine Disorders

Chemicals

Analgesics
Magnesium

Word Cloud

Created with Highcharts 10.0.0magnesiummigrainepatientsmaysufferersdeficiencyintracellularbloodtestsduetrialsdeficientcyanocobalamineoralMagnesiumsecondabundantcationessentialmanyprocessesappearsplayimportantrolepathogenesisRoutinereflecttruebodystoressince<2%measurableextracellularspace67%bone31%locatedintracellularlyLackpromotecorticalspreadingdepressionhyperaggregationplateletsaffectserotoninreceptorfunctioninfluencesynthesisreleasevarietyneurotransmittersMigrainedevelopgeneticinabilityabsorbinheritedrenalwastingexcretionexcessiveamountsstresslownutritionalintakeseveralreasonsstrongevidencemuchprevalenthealthycontrolsDouble-blindplacebo-controlledproducedmixedresultslikelynon-deficientincludedakingivingblindedfashiongrouppeopleperipheralneuropathywithoutregardlevelsintravenouswidelyavailableextremelysafeinexpensivecanhighlyeffectiveConsideringfeaturesfactpresenthalfroutineindicativestatusempirictreatmentleastwarrantedtreated

Similar Articles

Cited By